Is Nephros, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation metrics. The company appears to be undervalued, supported by a P/E ratio of 36, a PEG ratio of 0.23, and an EV to EBITDA ratio of 31.89. In comparison, its peer Nutriband, Inc. has a P/E ratio of -11.62, highlighting Nephros's relatively stronger valuation position.
Despite recent stock performance showing a significant decline of 19.30% over the past week compared to a 1.63% drop in the S&P 500, Nephros has delivered impressive returns year-to-date at 212.93%, significantly outperforming the S&P 500's 14.40%. This performance, combined with its attractive valuation ratios, suggests that Nephros, Inc. is positioned favorably in the market.